Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.

PMID:
31142661
2.

Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.

Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, Viswanadhapalli S, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2019 Apr 16;9(1):6124. doi: 10.1038/s41598-019-42313-8.

3.

Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression.

Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Cui X, Lai Z, Mohammad TA, Gupta YK, Huang TH, Huang Y, Chen Y, Rao MK.

Sci Adv. 2018 Oct 3;4(10):eaar8263. doi: 10.1126/sciadv.aar8263. eCollection 2018 Oct.

4.

Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner A, Vadlamudi RK.

Cancer Res. 2018 Jun 15;78(12):3176-3189. doi: 10.1158/0008-5472.CAN-17-3470. Epub 2018 Apr 16.

5.

Nox4 is a Target for Tuberin Deficiency Syndrome.

Shi Q, Viswanadhapalli S, Friedrichs WE, Velagapudi C, Szyndralewiez C, Bansal S, Bhat MA, Choudhury GG, Abboud HE.

Sci Rep. 2018 Feb 28;8(1):3781. doi: 10.1038/s41598-018-21838-4.

6.

Cross-talk between miR-471-5p and autophagy component proteins regulates LC3-associated phagocytosis (LAP) of apoptotic germ cells.

Panneerdoss S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Timilsina S, Mohammad TA, Chen Y, Drake M, Vuori K, Kumar TR, Rao MK.

Nat Commun. 2017 Sep 19;8(1):598. doi: 10.1038/s41467-017-00590-9.

7.

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.

8.

Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR.

Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.

9.

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.

Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK.

Oncogene. 2017 Apr 27;36(17):2423-2434. doi: 10.1038/onc.2016.395. Epub 2016 Nov 28.

10.

Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.

Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2016 Apr 29;6:24185. doi: 10.1038/srep24185.

11.

Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation.

Thakur S, Viswanadhapalli S, Kopp JB, Shi Q, Barnes JL, Block K, Gorin Y, Abboud HE.

Am J Pathol. 2015 Aug;185(8):2168-80. doi: 10.1016/j.ajpath.2015.04.014. Epub 2015 Jun 10.

12.

NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways.

Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B, Abboud HE.

Circulation. 2015 Feb 17;131(7):643-55. doi: 10.1161/CIRCULATIONAHA.114.011079. Epub 2015 Jan 14.

Supplemental Content

Loading ...
Support Center